Skip to main content
Post-Cardiac Arrest SyndromeHeart and circulationCombination productPhase 3

What this study is

XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management [TTM]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).

What's being tested

  • Xenon

    Intervention · COMBINATION PRODUCT

    50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.

Study details

Official title
XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome
Sponsor
Invero Pharma, Inc.
Conditions
Post-Cardiac Arrest Syndrome
Enrolling
1,436 people
Starts
2026-03
Est. completion
2030-05
Design
Single-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗